Terminal Illness and Real Estate: When to Sell vs. Inherit
A terminally ill woman faces a $100,000 capital gains bill on her rental condo. Experts weigh whether selling now or passing it on makes more financial sense.
A terminally ill woman with a rental condominium occupied by her younger son is weighing whether to sell the property now and absorb a roughly $100,000 capital gains tax hit, or hold the asset and allow it to pass to her heirs upon her death, according to a financial advice column published by MarketWatch.
The question carries significant tax implications. Assets transferred at death typically receive a "stepped-up" basis under current U.S. tax law, resetting the cost basis to the fair market value at the time of the owner's death. That provision can effectively eliminate embedded capital gains, potentially saving heirs tens of thousands of dollars compared with selling during the owner's lifetime.
Read more How to Add a Teen Driver to Your Car Insurance Affordably →
The situation is complicated by the son's reported intention to move out of the condo and relocate with friends, removing a key personal-use consideration from the equation. With no family member planning to occupy the property long-term, the estate-planning calculus shifts more squarely toward tax efficiency and liquidity needs.
Financial planners generally caution seriously ill clients against triggering large taxable events unnecessarily, particularly when the stepped-up basis rule could render those gains moot for heirs. However, individual circumstances — including the owner's immediate cash needs, outstanding debts, estate size, and state-level inheritance or estate taxes — can alter that general guidance considerably.
For terminally ill property owners, consulting an estate attorney and a certified public accountant before listing any appreciated asset is widely considered essential. The intersection of capital gains law, estate planning, and end-of-life financial needs is complex enough that a one-size-fits-all answer rarely applies. Continue reading at MarketWatch.com